Covance's acquisition will create business ops, Quintiles chief says; INC shuffles its C-suite;

> LabCorp's ($LH) soon-to-close acquisition of Covance ($CVD) will create opportunities for Quintiles ($Q), CEO Tom Pike said. More

> INC Research ($INCR) has changed things around in its C-suite, promoting COO Alistair Macdonald to president and appointing CNS President Michael Gibertini to the newly created role of president of clinical development. News

> Charles River Laboratories ($CRL) is considering reopening a long-dormant preclinical research operation in Massachusetts. Story

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.